First patient worldwide dosed with investigational DS1025, a potential first-in-class CD25 directed antibody drug conjugate being evaluated in patients with advanced solid tumors OSAKA, Japan, Oct. 19, 2026 /PRNewswire/ -- On August 18, 2026, the Department of New Experimental...
Hence then, the article about kansai medical university hospital administers first patient dose of ds1025 in global phase 1 clinical trial sponsored by daiichi sankyo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kansai Medical University Hospital Administers First Patient Dose of DS1025 in Global Phase 1 Clinical Trial Sponsored by Daiichi Sankyo )
Also on site :
- New species of sperm whale identified from fossils found in Gunma
- Lexsoft Systems Partners With Clio to Bring Clio's Legal AI Platform to Law Firms and Legal Departments Across EMEA
- ‘Barry Loser’ Animated Series, Based on Bestselling U.K. Children’s Books, Finds Italian Partners Ahead of Rome’s MIA Market (EXCLUSIVE)